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To prospectively study patients’ preference for and the lifetime of the Groningen Ultra Low Resistance
(GULR) and Provox2 tracheo-esophageal shunt prosthesis (TESP, plural TESPs) in post-laryngectomy
patients. Eighty post-laryngectomy patients were included in 4 oncological centers in the Netherlands.
We used a repeated measures design study with 4 randomized groups in a partial cross-over design using
3 consecutive TESPs (3 intervals) in different orders. (Group 1: GULR-GULR-GULR; Group 2: GULR-GULR-
Provox2; Group 3: Provox2-Provox2-GULR; and Group 4: Provox2- Provox2-Provox2). Replacement dates
and reasons for replacement were monitored with questionnaires as were patients’ preferences for GULR
or Provox2. A great variability of lifetime within and between groups was seen. Mean lifetimes found (all
groups and intervals added) were 106.2 and 102.7 days, and median lifetimes were 76 and 65 days for
GULR and Provox2, respectively. Lifetime showed no signiﬁcant differences between groups, intervals,
and TESP types. Many patients dropped out due to reasons having to do with GULR-characteristics
(n = 21). The main dropout reason was ‘‘high phonating resistance (HPR)’’ (57.1%). Only 10 patients pre-
ferred GULR. A signiﬁcantly larger number of patients (n = 39, 79.6%) preferred Provox2 either by choice
or by dropping out due to GULR-characteristics (P < 0.001). The main replacement reasons were ‘‘leakage
though TESP’’ (GULR 59.1%, Provox2 52.1%) and HPR (GULR 15.9%, Provox2 12.7%). No signiﬁcant differ-
ences in lifetime between GULR and Provox2 were found. The patients’ preference for Provox2 was sig-
niﬁcant (P < 0.001). Patients’ preference was a more important outcome measurement in TESP
effectiveness than device lifetime.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
In speech rehabilitation after total laryngectomy, the state-of-
the-art method used is the silicone rubber tracheo-esophageal
shunt prosthesis (TESP, plural: TESPs). To enable patients to pho-
nate after surgery, a TESP is positioned in the tracheo-esophageal
ﬁstula made during the laryngectomy. This TESP has a one-way-, Neus-, en Oorheelkunde,
. Tel.: +31 503612541; fax:
), w.j.post@rug.nl (W.J. Post),
@kno.umcn.nl (F.J.A. van den
ein), b.f.a.m.van.der.laan@-
r OA license.valve mechanism opening towards the esophagus when the
patient exhales while closing off the tracheostoma. This allows
the patient to phonate as air passing through the TESP causes
vibration of the neopharynx. Several types of TESPs are available.1,2
In the Netherlands and the rest of Europe, the Provox2 and the
Groningen Ultra Low Resistance (GULR) TESPs are the ones most
frequently used. Both have a limited lifetime and need to be re-
placed on a regular basis. Many studies have investigated the life-
time of the different TESPs used nowadays.3–11 The main reasons
for TESP replacement are leakage of ﬂuids through the TESP or
an increased airﬂow resistance during phonation, both caused by
biolﬁlm formation on the TESP surface.12
The burden of the replacement on laryngectomees is substan-
tial. The procedure has to be performed in an ENT outpatient clinic
and can be uncomfortable.
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lifetime (65 days) was signiﬁcantly longer than the mean Provox2
lifetime (42 days). The median lifetime for Provox2 and GULR was
40 and 48 days, respectively.3
The aim of our study was to compare the Provox2 and GULR
TESPs, and evaluate patients’ preference for one of these types.
We hypothesized that the GULR would have a longer lifetime than
the Provox2, that the GULR and Provox2 would otherwise have
comparable characteristics (i.e. anterograde replacement method,
phonating resistance), and that, due to a longer lifetime, patients
would prefer the GULR.
Methods
We performed a multicenter prospective randomized clinical
repeated measures trial to study the lifetime of GULR and Provox2.
The secondary study parameter was the patients’ preference for
one of the two TESPs.
Study population
We included 80 laryngectomees aged over 45, with at least
6 months of TESP experience and at least one prior anterograde
replacement. Excluded were patients with recurrent carcinoma,
no usage of their TESP, or those unﬁt to undergo anterograde
replacement. We included 55 patients at the University Medical
Center Groningen (UMCG), 7 at the Radboud University Nijmegen
Medical Centre, 13 at the Medisch Centrum Leeuwarden, and 5 pa-
tients were included from the VU University Medical Center. The
study was approved by the ethical committees in these institutions
and all patients gave their informed consent.
Study design
In each subject a follow-up of three consecutive TESPs was car-
ried out. The subjects were randomized into four groups, each with
different orders of TESP types (Table 1). In the baseline interval, pa-
tients were using their pre-study TESP (GULR or Provox2). Interval
0 was the run-in period, in which patients were getting used to the
TESP type used in Interval 1. This ruled out any carry-over effects
from their baseline TESP. Interval 1 was the ﬁrst and Interval 2
was the second intervention period. In Interval 2, Groups 2 and 3
switched to the other TESP type. Post-study preference depicts
the patients’ TESP type of preference. We chose a repeated mea-
sures design to investigate the possible positive effect of using sev-
eral TESPs of the same type consecutively, in terms of lifetime or
users’ convenience.
Power analysis was based on the comparison of the mean life-
time of two consecutive equal TESP types in Groups 1 and 4. To de-
tect lifetime difference with an 80% power and a 5% two-sided
alpha, and to create a balanced partial cross-over design, each
group needed 17 patients. Taking a dropout rate of 15% into ac-
count, 80 patients had to be included.Table 1
Study design.
Group N Baseline interval Interval 0
1 20 GULR/Provox2 GULR
2 20 GULR/Provox2 GULR
3 20 GULR/Provox2 Provox2
4 20 GULR/Provox2 Provox2
Baseline Interval: interval pre-study.
Interval 0: run-in period, patients are getting used to TESP studied in Interval 1.
Intervals 1 and 2: intervention intervals.
Post-study Preference: TESP of preference of the patient after completing the study.Materials
TESP lifetime was monitored by registering the replacement
dates.
Patients’ preference for GULR or Provox2 was evaluated by an
explorative questionnaire at the end of the study. Moreover we ex-
tended this by deﬁning ‘‘dropout due to TESP characteristics’’ as
the patient’s preference for the other TESP type.
Replacement reasons were carefully monitored by a question-
naire ﬁlled out by the physician doing the replacement.
Statistics
First, the randomization was tested by comparing the groups.
Mean age was compared with ANOVA. Sex distribution in the
groups was compared using the X2-test. The location of inclusion
was divided into ‘‘UMCG’’ and ‘‘non-UMCG’’ in order to evaluate
the non-UMCG patients percentages in all groups (X2-test).
Furthermore, the causes of missing data due to dropout of pa-
tients were considered. Some data were in fact missing because
we presented the study before all subjects had actually completed
the study. We therefore qualitatively evaluated the effects that
these missing data might have on our results.
Descriptive statistics were also used on the raw data in order to
evaluate the means, medians, and standard deviations of lifetime
in days per TESP type per interval. Since lifetime distribution was
not normal, we used logarithmically transformed data (‘‘log-life-
times’’). First, we compared the log-lifetime of two types of TESPs
in Interval 0, meaning the log-lifetime in Groups 1 and 2 (GULR)
compared to the log-lifetime of Groups 3 and 4 (Provox2). The
same comparison was made in Interval 1. Continuing in this fash-
ion, the log-lifetimes in Interval 2 were compared using Groups 1
and 3 (GULR) and Groups 2 and 4 (Provox2). All log-lifetime com-
parisons were made using students’ t-test and shown in box plots.
In all tests, a P < 0.05 was considered signiﬁcant. All groups then
ended up being compared for all intervals using multilevel analysis
in order to take into account correlation between measurements
within patients.
Finally, to test whether the preference for GULR and Provox2
was the same, we used binomial test, and TESP exchange reasons
were evaluated and described.Results
The following is our data collected in three years and 9 months
after the ﬁrst inclusion. We found no signiﬁcant differences in
mean age between the groups (P = 0.51). The sex distribution in
our study population is ratio 10:1 (M:F), consistent with the liter-
ature.13–15 However, in Group 3 the sex distribution was 15:5,
while in the other groups the sex distribution was 19:1. Neverthe-
less, no signiﬁcant relationship between groups and sex was found
(P = 0.08). Moreover, no relationship between location and group
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missing data, and timing of dropout per interval per group. Clearly,
many patients (n = 41) did not complete the study; this was due to
the following reasons. Fourteen patients were included but
dropped out before Interval 0 (thus in the pre-study interval).
These are displayed in the column labeled ‘‘no start’’ in Interval
0. In Group 1 dropout was due to emigration (n = 1), death
(n = 1), and secondary tumor (n = 1). Group 2 lost patients prestart
due to death (n = 2), no further TESP usage (n = 1), and personal
reasons (n = 1). In Group 3 death occurred once (n = 1) prestart.
Furthermore, 6 patients (Group 1 (n = 2), Group 3 (n = 2), and
Group 4 (n = 1)) did not start in Interval 0 due to reasons that are
unclear. In addition 21 patients dropped out due to characteristics
of the GULR (explained later); this usually occurred at the moment
of TESP exchange. When death or other dropout reasons occurred
(n = 6) during the intervals, we used this date as the end of the
interval. Nine patients were still in the study at the moment of
our analysis (‘‘pending’’). The timing for all dropouts and ‘‘pending’’
patients are depicted in Table 2.
Lifetime
Table 3 shows the mean and median lifetime of the Provox2 and
GULR added per interval, along with all intervals added per TESP
type. There is great variability in lifetime within the groups. For
example, the standard deviation of GULR lifetime in Interval 0 is
larger than the mean lifetime.
Fig. 1 shows lifetime in days in three intervals separated by
group. There is great variability between the groups despite the
fact that they were expected to be similar (same TESP type).
Looking at the data, there was no normal distribution in all the
intervals in terms of lifetime in days; therefore, we used a log
transformation on the data. Comparing log-lifetime in Groups 1Table 2
Number of completed intervals per group, missing data, and timing of dropout per interv
Interval 0
Group TESP type No start At risk
1 GULR 5 (of 20) 15
2 GULR 4 (of 20) 16
3 Provox2 4 (of 20) 16
4 Provox2 1 (of 20) 19
Total 14 (of 80) 66
Interval 1
Group TESP type No start At risk
1 GULR 0 8
2 GULR 0 14
3 Provox2 2a 14
4 Provox2 2b 16
Total 4 52
Interval 2
Group TESP type No start At risk
1 GULR 0 7
2 Provox2 1c 7
3 GULR 1d 13
4 Provox2 0 15
Total 2 42
TESP type: type of TESP used by the groups in each interval.
No start: in Interval 0 patients did not start due to various reasons; no start in Intervals 1
or 2, respectively) due to dropout.
At risk: number of patients that started in the interval.
GULR dropout: patients who dropped out due to characteristics of the GULR.
Pending: subjects that are still in the middle of the interval.
Completed interval: an interval that has ended either because of TESP removal or becau
Completed study: patients that ﬁnished Interval 2 or died in Interval 2.
a Dropout due to problems with ﬁstula (n = 1) and death (n = 1) in Interval 0.
b Dropout due receiving the wrong type of TESP (n = 1) and due to ﬁstula problems (n
c Dropout after Interval 1 due to personal reasons (n = 1).
d No more TESP usage (n = 1).and 2 with Groups 3 and 4 in Interval 0 and Interval 1, respectively,
no signiﬁcant difference between these groups was found (P = 0.64
and 0.89, respectively). And, although Interval 2 in Group 3 seemed
different (i.e. shorter GULR lifetime), when comparing log-lifetime
in Groups 1 and 3 with Groups 2 and 4 in Interval 2, no signiﬁcant
difference was actually found (P = 0.44).
In addition, using Multilevel Analysis showed no signiﬁcant dif-
ference in lifetime between GURL and Provox2. No beneﬁcial effect
for lifetime was shown when patients used the same TESP type
consecutively.
Dropout and preference of the patient
Table 4 is a survey of the completed subjects and the patients
that dropped out due to GULR-related characteristics. No patients
dropped out due to Provox2-related reasons.
Remarkably, many subjects (n = 21) using GULR dropped out
due to reasons concerning GULR characteristics (‘‘dropout due to
GULR’’). The most important dropout reason was ‘‘high phonating
resistance’’ (HPR) (n = 12, 57.1%): some subjects could not produce
any sound (n = 4) or very little with maximum effort (n = 5) di-
rectly after the GULR placement. Some patients (n = 3) found the
GULR phonating resistance in Interval 1 too high and thus dropped
out. The second dropout reason was leakage of the GULR directly
after insertion (n = 3). One of the patients who dropped out due
to HPR had also experienced minor direct leakage. Other reasons
for dropout were ‘‘cleaning problems’’ (n = 1), ‘‘increased shortness
of breath’’ in an asthma patient (n = 1), ‘‘problematic replacement’’
(n = 3), and ‘‘sizing problems’’ (n = 1) due to leakage around the
TESP; in this latter case, the smallest GULR size was too large
(5 mm compared to Provox2 4.5 mm).
When adding the total GULR-related dropout and the number of
subjects who ended up with a preference for Provox2, we found aal.


















or 2 means that patients ﬁnished Interval 0 or 1 but did not start the next interval (1
se of death of the patient.
= 1) in Interval 0.
Table 3
Mean, median, and standard deviation of lifetime in days per interval per type of TESP, and all intervals added per type of TESP.
Type of TESP Interval 0 Interval 1 Interval 2 Summed intervals
Mean Median SD N Mean Median SD N Mean Median SD N Mean Median SD N
GULR 129.0 73.5 154.4 22 118.8 73.0 130.8 15 94.9 41.5 95.2 12 117.5 73.0 133.0 49
Provox2 120.1 82.5 111.6 34 135.7 84.0 155.7 29 116.2 102.5 96.7 18 124.8 84.0 125.2 81
Figure 1 Lifetime in days in all intervals per group per interval. GULR is Groningen Ultra Low Resistance.
Table 4
Survey of completed subjects, dropout rates due to GULR-related reasons, and patients’ preference.
Group Interval 2 completed Preference Provox2 Preference GULR Dropout due to GULR Total Provox2 preference Total known preference
1 6a 1 4 8 9 13
2 6 5 1 8 13 14
3 6 3 3 5 8 11
4 12a 9 2 0 9 11
Total 30 18 10 21 39 49
Interval 2 completed: patients ﬁnished the study or died in Interval 2.
Preference Provox2: patients completed the study with Provox2 preference.
Preference GULR: patients completed the study with GULR preference.
Dropout due to GULR: patients that dropped out due to GULR-related reasons.
Total Provox2 preference: patients that either completed the study with Provox2 preference or dropped out due to GULR-related reasons.
Total known preference: total number of patients for whom preference is known.
a One subject died in Interval 2, which means the study was completed but preference was unknown.
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having GULR preference. Thus 79.6% of the patients preferred using
a Provox2 voice prosthesis (P < 0.001).
TESP replacement reasons
The number of replacements evaluated was 44 for GULR and 71
for Provox2. There are many reasons to replace a TESP. The most
important replacement reasons in our study were: leakage though
the TESP (GULR 59.1% and Provox2 52.1% of all replacements); HPR
(GULR 15.9% and Provox2 12.7% of all replacements); and leakage
around the TESP (GULR 4.6% and Provox2 4.2% of all replacements).
Other less frequent replacement reasons were growth of granula-
tion tissue around or over the TESP, or dislocation of the TESP.Discussion
The mean device lifetimes we found were 106.2 and 102.7 days,
and median lifetimes were 76 and 65 days for GULR and Provox2,
respectively. These ﬁgures are consistent with the literature,3–11 in
which great variability in mean (333 to 1478 days) and median
(3011 to 1446 days) lifetime in Provox2 is shown, and also a high
range with measured lifetimes varying from 75 to 7356 days. The
GULR lifetime results are comparable with the literature as well
(mean 653 to >95.2 (range 14–182)7 and median 483). Even though,
most of these studies had retrospective designs, in contrast to our
study, our results showed the same kind of great variability.
According to our protocol, new patients were to be included in
case where there were more than four dropouts per group.
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result instead of normal dropout, that is, patients’ preference, we
decided not to replace these patients. Moreover, an ethical conﬂict
would thus arise: Shouldwe exposemore patients to a TESP that ap-
pears unfavorable to the patient? As a result, wewere able to collect
less data on GULR lifetime (especially in Interval 2) than expected,
which negatively inﬂuenced the power of the study. Furthermore,
ending the studybeforeall subjectshadﬁnishedcausedmissingdata
in the GULR Interval 2, though for only three patients. In light of the
very signiﬁcant preference, the beneﬁt of waiting for these patients
to ﬁnish would not have affected the results.
Interestingly, patients’ preference was highly signiﬁcantly in fa-
vor of Provox2. This ﬁnding is new in literature. It suggests that other
TESP aspects besides lifetime are equally as important for the pa-
tients’ comfort. Themain factor is the HPR seen in the highGULR-re-
lated dropout. Other factors of discomfortwere ‘‘cleaning problems’’
‘‘problematic replacement procedures’’, ‘‘sizing problems’’, and ‘‘in-
creased shortness of breath’’ in an asthma patient. Consequently,
these factors could be useful in designing a new TESP.
Our hypotheses assumed the phonating resistance of Provox2
and GULR to be comparable. However, the studies on the phonating
characteristics of several TESP types, both in vitro and in vivo, unfor-
tunately are all characterized by differentmethods used tomeasure
theTESPs’ aerodynamics.7,8,11,16–18Chungandcolleagues7measured
a mean maximum phonation time (MPT) of 16 s (range 7–42 s) one
week afterGULR insertion. Terada and colleagues8measured amean
MPT in Provox2 of 15.1 s (range 8–28 s). The timing of both these
measurements with respect to the moment of insertion of the Prov-
ox2 is unclear. While theMPT in both TESPs is comparable, the high
GULR dropout due to HPR was unexpected.
Strikingly, the second most important reason for dropout was
TESP leakage immediately after insertion (14.3% of all dropouts).
This would suggest that the TESP valve was constantly open, which
could be caused by low intra-esophageal pressure or a rigid TESP in
a small ﬁstula. Some hypothesize that cold TESP temperature
immediately after insertion causes additional rigidity and leakage.
The immediate leakage and HPR seem contrasting, and the mech-
anism behind these characteristics is unclear, even more so consid-
ering the one patient who experienced both leakage and high
phonation resistance at the same time.
Leakage through the TESP was the main replacement reason,
which is consistent with the literature on older types of TESPs.19
Oosterhof and colleagues20 retrospectively compared the Gronin-
gen Low Resistance (GLR) and Provox2 replacement reasons and
found higher leakage percentages in Provox2 (GLR 57% and Prov-
ox2 76%). Their percentage of leakage around the TESP was higher
(14% in GLR and Provox2). HPR as replacement reason in their
study was 12% (GLR and Provox2). We found a higher percentage
of HPR in GULR (15.9%), which contrasts with Chung and col-
leagues18 who showed a signiﬁcantly lower in vitro airﬂow resis-
tance in GULR compared to GLR. This suggests that HPR directly
after insertion and HPR as a replacement reason are two separate
entities with different origins. Bioﬁlm formation might be of inﬂu-
ence on ‘‘later onset’’ HPR, while TESP design seems to inﬂuence
the HPR directly after insertion.
When reviewing our results, we found no signiﬁcant differences
between GULR and Provox2. However, the preference of patients
for Provox2 was signiﬁcant (P < 0.001). Therefore, we recommend
Provox2 in the voice rehabilitation of post-laryngectomy patients.
Since patients’ preference was a leading factor in our results, we
suggest that in future studies on TESP effectiveness patients’ pref-
erence should be considered as an outcome measurement equally
as important as the median device lifetime ﬁgure.Conﬂict of interest statement
None declared.
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